NOT KNOWN FACTUAL STATEMENTS ABOUT IL-2 THERAPY FOR MELANOMA

It can be nicely understood that IL-two is usually a pleiotropic cytokine positioned on the crossroads of T cell activation and regulation. Therefore, it really is very important to engineer an IL-two molecule that is definitely biased toward effector cells bearing the intermediate affinity receptor, for example naïve and memory CD8+ T cells and N